Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene by Mercado, Pablo Arrisi et al.
Depletion of TDP 43 overrides the need for exonic
and intronic splicing enhancers in the human
apoA-II gene
Pablo Arrisi Mercado
1, Youhna M. Ayala
1, Maurizio Romano
1,2,
Emanuele Buratti
1 and Francisco E. Baralle
1,*
1International Centre for Genetic Engineering and Biotechnology, Padriciano 99, I-34012 Trieste, Italy and
2Department of Physiology and Pathology, University of Trieste, Via A. Fleming 22, 34127 Trieste, Italy
Received August 2, 2005; Revised September 19, 2005; Accepted September 27, 2005
ABSTRACT
Exon3ofthehumanapolipoproteinA-II(apoA-II)gene
is efficiently included in the mRNA although its
acceptor site is significantly weak because of a pecu-
liar (GU)16 tract instead of a canonical polypyrimidine
tract withinthe intron2/exon 3 junction. Our previous
studies demonstrated that the SR proteins ASF/SF2
and SC35 bind specifically an exonic splicing
enhancer (ESE) within exon 3 and promote exon 3
splicing. In the present study, we show that the ESE
is necessary only in the proper context. In addition,
we have characterized two novel sequences in the
flankingintronsthatmodulateapoA-IIexon3splicing.
There is a G-rich element in intron 2 that interacts
with hnRNPH1 and inhibits exon 3 splicing. The
second is a purine rich region in intron 3 that binds
SRp40 and SRp55 and promotes exon 3 inclusion in
mRNA. We have also found that the (GU) repeats in
the apoA-II context bind the splicing factor TDP-43
and interfere with exon 3 definition. Significantly,
blocking of TDP-43 expression by small interfering
RNA overrides the need for all the other cis-acting
elements making exon 3 inclusion constitutive even
in the presence of disrupted exonic and intronic
enhancers. Altogether, our results suggest that
exonic and intronic enhancers have evolved to bal-
ance the negative effects of the two silencers located
in intron 2 and hence rescue the constitutive exon 3
inclusion in apoA-II mRNA.
INTRODUCTION
The pre mRNA splicing process leading to the synthesis of
mature mRNA takes place in the spliceosome, a complex of
small ribonucleoprotein particles (snRNPs) and splicing
factors and is ﬁnely modulated (1,2). Cis-acting elements
that inﬂuence splice site selection include the 50 and 30 splice
sites, the branch point sequence and the polypyrimidine
tract. Beyond the above mentioned canonical cis-acting ele-
ments, accessory sequences, such as exonic splicing enhancers
(ESEs), exonic splicing silencers (ESSs), intronic splicing
enhancers (ISEs) and intronic splicing silencers (ISSs) are
also important for the deﬁnition of an exon (3,4).
Recently, we have demonstrated the existence of an ESE
within the third exon of the apolipoprotein A-II (apoA-II) gene
that speciﬁcally binds the SR proteins ASF/SF2 and SC35.
The mutagenesis of this element prevented the binding of
these trans-acting elements and caused in vivo skipping of
exon 3 (5). Moreover, overexpression of ASF/SF2 and SC35
improved exon 3 inclusion, further supporting the positive
involvement of these factors in exon 3 deﬁnition. Mechanis-
tically, the recruitment of ASF/SF2 and SC35 might be acting
as part of a scaffold to allow the recognition of the 30 splice
site, whose polypyrimidine tract is weak because of the pecu-
liar (GU)16 stretch adjacent to the intron/exon junction, which
previous functional studies have indicated as a controller of
exon 3 splicing (5). In this paper we show that the (GU)16
stretch in the apoA-II context also binds the TDP-43 protein,
a splicing factor implicated in the CFTR exon 9 skipping
through its interaction with the (GU) repeats located within
the 30 splice site of CFTR intron 8 (6). Thus, we have revisited
the function of the (GU) tract in apoA-II intron 2 by demon-
stration that its interaction with TDP-43 has an inhibitory
role for the splicing of apoA-II exon 3, similarly to what was
observed for the splicing of CFTR exon 9. Moreover, we have
characterized a novel negative cis-acting element within
apoA-II IVS2 and a positive cis-acting element in IVS3
involved in the control of the apoA-II exon 3 splicing. Inter-
estingly, RNA interference against TDP-43 abolishes the
effects of both exonic and intronic enhancer disruption. This
result seems to indicate that ESEs and ISEs in the human
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TDP43 binding to the (GU) repeats.
MATERIALS AND METHODS
Constructs
The wild-type and A97T sets of the pcDNApoIVS2 and
pcDNApoIVS3 constructs were generated throughout over-
lap PCR method using apoA-II gene and apoA-II cDNA as
templates. All pApo constructs carrying deletions or point
mutations were generated by site-directed mutagenesis using
standard PCR conditions. The identity of all constructs
was checked by a CEQ2000 sequencer (Beckman Coulter,
Fullerton, CA) according to the manufacturer’s instructions.
Constructs PTBApo-wt and PTBApo-A97T as well as
PTBApo-wt-ISEmut and PTBApo-A97T-ISEmut were gener-
ated as follows: the apoA-II exon 3 plus portions of both
ﬂanking introns 2 (174 nt) and 3 (116 nt) were PCR-
ampliﬁed from pApo-wt and pApo-A97T, respectively, and
ﬁlled in with DNA polymerase (Klenow). The fragment was
then inserted in a modiﬁed version of the a-globin–ﬁbronectin
EDB minigene in which this alternatively spliced exon had
been removed to generate a unique Nde I site which was
subsequently ﬁlled in with DNA polymerase I (Klenow) treat-
ment, making it suitable for the insertion of the exon and
its ﬂanking introns under study. Constructs carrying partial
deletions of either intron 2 or intron 3 were prepared starting
from templates pApo-wt and pApo-A97T. The deletions were
performed by overlapping PCRs products obtained using
suitable primers. Generation of constructs mg(GU)16 and
mgD(GU) for in vitro experiments was carried out amplifying
from pApo-wt and D(gu) plasmids (5) with the following
couple of primers: SXhoI (50-cccgctcgagcactgttaccaacatga-
agct-30) and HindIII/SacII AS (50-ttttccgcggaagcttctctgcgaa-
ttctaagcctaatctgccctaa-30). Whereas generation of construct
(GU)16-Ex3 was performed with the primers: ApoAII-TG/
Exon3–50 (XhoI) (50-cccgctcgagggacccagctgaaaagag-30) and
ApoAII-Exon3–30 (SacII) (50-ttttccgcggaagcttttggcctcggcct-
gaa-30).
Transfections
The DNA used for transient transfections was prepared with
JetStar puriﬁcation kit (Genomed, GmbH, Lo ¨hne, Germany)
following the manufacturer’s instructions. Then, 3 mg of DNA
construct was transfected in 3 · 10
5 human hepatocarcinoma
Hep3B cells using Qiagen Effectene transfection reagents.
Total RNA was extracted using RNAwiz reagent (Ambion,
Austin, TX) and retro-transcribed with poly(dT) primer. To
amplify only the messenger derived from the transfections,
PCRs were carried out with primers Ex1–1221 S (50-accaag-
gacagagacgctggct-30) and Not/Cla rev (50-tctggacactgcggccg-
catcg-30) for constructs derived from pApo gene system and
with primers a (50-caacttcactcctaagccactg-30) and Bra (50-
gggtcaccaggaagttggttaaatca-30) for constructs derived from
the a-globin–ﬁbronectin EDB minigene (PTB). The condi-
tions used for the PCRs were the following: 94 C for 5 min
for the initial denaturation, 94 C for 30 min, 60 C for 1 min,
72 C for 1.5 min for 35 cycles, and 72 C for 7 min for the ﬁnal
extension. The PCRs were optimized to be in the exponential
phase of ampliﬁcation. For the SR protein overexpression
experiments, 2 mg of the constructs pApo-wt, pApo-ISE3m,
pApoA97T or pApoA97T-ISE3m was cotransfected with
2 mg of SRp40 and SRp55 coding sequences cloned into
pCG vector (a kind gift of Dr J. Caceres). The results of all
the transfections are the representative of at least three inde-
pendent experiments. In order to quantify the proportion of
alternative splicing, the relative amount of exon 3 skipping
was quantiﬁed by optical densitometry.
RNA electrophoretic mobility shift assay (EMSA)
and UV-crosslinking of protein and RNA
In order to generate the two different versions of human
apoA-II intron 3 ISE RNAs, EcoRI–SalI double digestion
was carried out on the construct pApo-wt and pApo-wt-ISE
mut and subsequently cloned in pBluescript (SK) plasmid
digested with the same enzymes. Once linearized with EcoRI,
the constructs were in vitro transcribed in the presence of
[a-
32 P]UTP for 60 min at 37 C and treated with DNase for
the same period of time. For EMSA, the [a-
32P]UTP-labeled
RNA probes (4–6 fmol) were incubated with 5.2 mM HEPES,
pH 7.9, 1 mM MgCl2, 0.8 mM magnesium acetate, 0.52 mM
DTT, 3.8% glycerol, 0,75 mM ATP, 1 mM GTP, 0.5 mg/ml
heparin and 30 mg of HeLa nuclear extract (4C Biotech,
Seneffe, Belgium) in a ﬁnal volume of 20 ml for 20 min
at room temperature. Following the addition of 5 mlo f
50% (v/v) glycerol and tracking dye, the complexes were
resolved on a 4% polyacrylamide gel (ratio of 19:1
acrylamide/bisacrylamide) in 75 mM Tris–glycine buffer
(75 mM Tris and 75 mM glycine) at 15–25 mA for 3–4 h
at 4 C. The gels were dried and exposed to X-OMAT AR
ﬁlms for 1–3 h. The UV-crosslinking assay was performed
by incubation of the [a-
32P]UTP-labeled RNA probes (1 ·
10
6 c.p.m./incubation) with 20 mg of HeLa nuclear extract
in 20 ml of ﬁnal volume at 30 C for 15 min. Final binding
conditions were 20 mM HEPES, pH 7.9, 72 mM KCl, 1.5 mM
MgCl2, 0.78 mM magnesium acetate, 0.52 mM DTT, 3.8%
glycerol, 0.75 mM ATP, 1 mM GTP and heparin at a 5 mg/ml
ﬁnal concentration as a nonspeciﬁc competitor. In the com-
petition experiments increasing amounts of cold RNA (the
molar ratios of cold/labeled RNA were 3 and 6) was also
added as a competitor 5 min before addition of the labeled
RNAs. The samples were then transferred in the wells of an
HLA plate (Intermed, Nunc, Roskilde, Denmark) and irradi-
ated with UV light on ice (800000 kJ for 5 min). Unbound
RNA was then digested with 30 mg of RNase A and 6 U of
RNase T1 (Sigma) by incubation at 37 C for 30 min. The
samples were then analyzed by 10% SDS–PAGE followed
by autoradiography.
Crosslinking of RNA to adipic
dehydrazide-agarose beads
Two synthetic RNA oligos IVS2-G123w, auaccuuuuuggggag-
ggggcagagagc, and IVS2n-G123m, auaccuuuuugcggagcg-
cgcagagagc (Dharmacon, Chicago, IL), were generated and
crosslinked to adipic dehydrazide–agarose beads. Afterwards
they were separately incubated with HeLa nuclear extract with
the addition of heparin to a ﬁnal concentration of 5 mg/ml.
Proteins were separated on a 10% SDS–PAGE gel and
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blotted onto a nitrocellulose membrane and probed with a
rabbit polyclonal anti-hnRNPH antiserum. Immunoblottings
were detected using the ECL chemiluminescence kit (Pierce,
Rockford, IL).
Immunoprecipitation of SR proteins and
TDP-43 following UV-crosslinking
The UV-crosslinking of labeled RNAs with commercial
HeLa nuclear extract was performed as described above.
After the 30 min incubation with RNase at 37 C, 150 mlo f
immunoprecipitation (IP) buffer (20 mM Tris, pH 8.0,
300 mM NaCl, 1 mM EDTA and 0.25% Nonidet P-40) was
added to each sample together with 1 mg of monoclonal
antibodies mouse anti-SR 1H4 (Zymed Laboratories Inc.,
San Francisco, CA) and incubated for 2 h at 4 C on a rotator
wheel. Afterward, 30 ml of protein A7G-Plus-agarose (Santa
Cruz Biotechnology, Santa Cruz, CA) was added to each
sample and incubated overnight at 4 C. The beads were sub-
jected to four washing cycles with 1.5 ml of IP buffer and
loaded on a 10% SDS–PAGE. The gels were run at a constant
rate of 30 mA for 3.5 h, dried and exposed for 4–6 days with a
Biomax Screen (Kodak, Rochester, NY). The [a-
32P]UTP-
labeled RNA probes mg(GU)16,m g D(GU) and (GU)16-Ex3
used for UV-cross linking/IP were treated as described
above, with the only difference that 1 mg of polyclonal anti-
serum against TDP-43was added. After a 2 h incubation, 30 ml
of Protein A/G-Plus Agarose (Santa Cruz Biotechnologies)
was added to each sample and the mixture was incubated
at 4 C overnight. The beads were then subjected to four
washing cycles with 1.5 ml of IP buffer and loaded onto an
SDS–PAGE. Gels were run at a constant 30 mA for  3.5 h,
dried, and then exposed for 4–6 days with a BioMax Screen
(Kodak). Three independent IP assays were carried out for
each antibody.
RNA interference against TDP-43
Hep3B cells (2 · 10
5) were seeded 24 h before the ﬁrst
transfection with the small interfering RNA (siRNA) oligo-
nucleotide speciﬁc for TDP-43 (Y. M. Ayala, personal
communication). Oligofectamine (3 ml) (Invitrogen BV,
Leek, The Netherlands) was combined with 13 ml of Optimem
medium (Invitrogen) and incubated for 7 min at room tem-
perature (RT) (reaction 1). Meanwhile, in a different tube, 2.5
ml of the TDP-43 siRNA was mixed with 180 ml of Optimem
(reaction 2). After the incubation, both reactions were mixed
and left for20 min atRT.Afterwards,the mix was added to the
cells and maintained in the incubator at 37 C and 6% of CO2
for 48 h. The cells were then washed with phosphate-buffered
saline (PBS) and the transfection procedure was repeated with
the difference that cells were maintained for only 24 h. Cells
were washed with PBS and transfected with 0.5 mg of each
minigene using Qiagen Effectene transfection reagents. RNA
extraction and RT–PCR analysis were performed using pri-
mers complementary to sequences in the ﬂanking ﬁbronectin
exonic sequences. Cell lysates were collected and analyzed for
hnRNP H1 endogenous protein expression by western analysis
using anti-H1 rabbit serum.
RESULTS
An intronic splicing enhancer is present
within apoA-II intron 3
Our previous studies have evidenced that (i) the 30 splice site
of IVS2 is weak because of the (GU) tract adjacent to the
acceptor site and (ii) a positive splicing cis-acting element
(ESEwt) is placed within exon 3 and its alteration by point
mutations (ESE-A97T) causes exon 3 skipping (5). In general,
the interplay among different exonic and/or intronic sequences
and the trans-acting factors can inﬂuence the recruitment of
the constitutive splicing factors U2AF65 and U1 to the 30 and
50 splice site, respectively. We were interested to identify other
apoA-II exon 3 splicing control elements eventually placed
within its intronic ﬂanking regions and to test these potential
cis-acting elements in an heterologous system. For this pur-
pose, the wild-type and A97T ApoA-II exon 3 (133 nt) with its
ﬂanking intronic regions (174 nt of intron 2 and 116 nt of
intron 3) were cloned into the third intron of the pTB vector,
which is an a-globin/ﬁbronectin reporter minigene system
used to study alternative splicing of several exons (7,8).
(Figure 1A). The splicing proﬁle from pTB minigenes over-
lapped those obtained with the pApo constructs (Figure 1B).
In fact, pTBApo-wt and pTBApo-A97T constructs yielded
5 and 85% of exon 3 exclusion (Figure 1B, lanes 3 and 4),
so mimicking substantially the splicing ratio from the corre-
sponding variants in apoAII gene context (Figure 1B, lanes 1
and 2). These results indicate that the 423 nt genomic fragment
of apoAII gene contains all the features important for efﬁci-
ent exon 3 inclusion in apoAII mRNA. Therefore, the pTB
constructs can be used to the following mapping of potential
intronic cis-acting elements that inﬂuence exon 3 splicing.
Initially, in order to verify the eventual presence of other
apoA-II exon 3 splicing control elements, we screened its
intronic ﬂanking regions looking for possible cis-acting ele-
ments whose sequence might resemble previously described
modulators of splicing. In order to look for other splicing
control elements in IVS3, we created a deletion of 97 nt in
intron 3 (from nt 1925 to 2022 in the apoA-II gene; GenBank
accession number X04898.1) so obtaining the construct
pApo-wt-D1925–2022 (Figure 1C). This 97 nt-deletion caused
a 40% skipping of the exon 3 (Figure 1E, lane 3). This obser-
vation supports the existence of one or more elements within
intron 3 that promote the inclusion of the apoA-II exon 3. We
noticed the presence of three G runs in intron 3 just 10 bp
downstream of the exon 3 donor splice site, namely I3G1 to
I3G3, and a polypurine-rich sequence between nt 1935 and
1960 (Figure 1C). As these elements are close to the splice
sites of exon 3, we have explored ﬁrst the possible effects of G
runs on the control of the apoA-II exon 3 splicing. To this aim,
we ﬁrst created mutants where the third, the ﬁrst two and
all the three G runs were disrupted by point mutations in
intron 3. However, the transient transfection of this mutant
did not show signiﬁcant changes in the apoA-II exon 3
splicing pattern in comparison with the pApo-wt construct
(Figure 1D). Thus, it is reasonable to exclude a role in the
splicingofexon3fortheGrunswithinintron3.Conversely,the
deletion of the purine-rich tract caused 25% apoA-II exon 3
skipping (Figure 1E, lane 4). In order to conﬁrm the enhancing
activity within nt 1941–1967, the continuity of the purine
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apoA-II gene and in the pTBApo contexts. Thus, constructs
pApo-ISE3m and pTBApo-ISE3m were generated (Figure 1A
and C, respectively). Point mutations within the potential ISE
placed in intron 3 caused 45% exon 3 skipping in the pApo
context and 55% exon 3 skipping in the pTBApo context
(Figure 1F, lanes 2 and 4, respectively). Thus, consistently
with the data obtained by the deletion, the results of point
mutations conﬁrmed the positive role for the polypurine
element (ISE3) independently from the context.
SRp40 and SRp55 overexpression enhances
splicing of apoA-II exon 3
Once veriﬁed the presence of a putative intronic splicing
enhancer within intron 3 (ISE3), we were interested in
identifying trans-acting factors possibly binding this region.
As a ﬁrst approach, EMSA was carried out by using two
in vitro transcribed RNAs carrying either the ISE3wt or the
ISE3 disrupted by the point mutation (ISE3m) (Figure 2A).
The analysis showed two bands of shifted material with the
transcript carrying the ISE3wt (upper complex, Uc, and lower
complex, Lc) and only one band with ISE3m RNA (Figure 2B,
compare lanes 3 and 4). A possible explanation for the
difference in the number and mobility of the RNA–protein
complexes might be the assembly of different factor/s upon
ISE3wt and ISE3m RNAs.
The purine-rich content of ISE3 was reminiscent of exonic
enhancer sequences, in fact ESE ﬁnder prediction of putative
SR protein binding sites (9) showed the presence within the
ISE of a high score site for SRp40 (data not shown). Total
UV-crosslinking proﬁles did not show additional differences
Figure1.AnISEsequenceislocatedwithinthehumanapoA-IIintron3.(A)Schematicrepresentationofthea-globin/fibronectinreportersystem(pTB)usedtotest
the effect of the mutation in the apoA-II exon 3 ESE in a heterologous system a-globin, fibronectin EDB exons and human apoA-II exon 3 are indicated in black,
shadedandwhiteboxes,respectively.Theblackcircleindicatesthe(GT)16tract.ThesuperimposedarrowsindicatetheprimersusedinRT–PCR.Theidentityofthe
band is indicated at the left side of the gel. (B) Splicing pattern analysis of the RT–PCR products derived from cellular RNA, stained by ethidium bromide and
separated on a 2% agarose gel. Comparison of the effect of the mutation A97T in the apoA-II exon 3 ESE when located in the pApo gene system and in the
heterologousa-globin/fibronectinreportersystem(pTB).(C)SchematicrepresentationoftheconstructscarryingdeletionandpointmutationsinthehumanapoA-II
intron3.Whiteboxes,thinlinesandtheblackcirclerepresentthehumanapoA-IIexonsandintronsandthe(GT)16tract,respectively.TheESEwtandESEA97Tare
indicatedassmallwhiteandblack boxeswithintheapoA-IIexon3,respectively.PartofthehumanapoA-IIintron3sequences.TheGrunsarein bold.Theasterisk
indicates a 26 bp poly-purine rich region (underlined) deletion in the apoA-II intron 3. Arrowheads indicate the different point mutations within the polypurine
regioninintron3.(D)Splicingpatternanalysisbyethidiumbromidestainingofa2%agarosegelelectrophoresisoftheRT–PCRproductderivedfromcellularRNA.
The disruptionofthe G runsin IVS3 wascarriedoutas followed:in theconstruct pApo-DI3G3 ggggctg!gcttatg,in pApo-DI3G1–2gggcaagggg!tcacaagcgc,and
in pApo-DI3G1–3 gggcaaggggttcagggg!tgtcaagcattcatgcg. (E) Splicing pattern analysis of Hep3B transfected cells with constructs in which partial deletion of
the intron 3 were carried out. (D) Schematic representation of the human apoA-II exon 3 and its flanking introns cloned in the a-globin/fibronectin reporter
system (pTB). a-globin, fibronectin EDB exons and human apoA-II exon 3 are indicated in black, shaded and white boxes, respectively. The black circle indicates
the(GT)16tract.Thesmallwhiteboxwithintheexon3andthewhiterectanglein theintron3representsthe ESEandtheISE,respectively.Arrowheadsindicatethe
differentpointmutationswithinthepolypurineregioninintron3.(F)ComparisonofthesplicingprofilesproducedbythemutationsintheISEbothinthepApogene
system context and in the pTB reporter minigene. Relative amounts of exon 3 skipping are indicated below the lane numbers. The variability among three different
experiments was always <20%.
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recruitment of SR proteins by the ISE3wt and ISE3m tran-
scripts, we carried out UV-crosslinking analysis followed
by immunoprecipitation using the monoclonal antibody 1H4
(mAb1H4),that recognizes mainlythe phosphorylateddomain
of SRp40, SRp55 and SRp75 (10). The results showed that
the ISE3wt but not the ISE3m RNA was able to immuno-
precipitate both SRp40 and SRp55 (Figure 2C). Afterward,
to test functionally the putative positive effects of SRp40 and
SRp55, two pTBApo constructs carrying both the ESE in
exon 3 and the ISE3 mutated were generated. Then, plasmids
capable to express these SR proteins were cotransfected ﬁrst
along with pApo-wt and pApo-ISE3m. Figure 2D shows that
cotransfection of pApo-wt with both SRp40 and SRp55 pro-
moted full exon 3 inclusion (upper panel, lanes 2 and 6) when
compared with the cotransfections with the control vector
(upper panel, lanes 1 and 5). However, the overexpression
of SRp40 and SRp55 with the construct carrying the ISE3m
point mutation showed no signiﬁcant variation in exon 3
inclusion levels (upper panel, lanes 4 and 8). In order to high-
light better the effects of SR proteins overexpression, we
repeated the cotransfection experiments with pApo-A97T
and pApoA97T-ISE3m constructs. Because of the disruption
of the ESE within exon 3, the basal level of exon 3
exclusion is higher and the effects of SR proteins are more
detectable. However, the positive effects ofthe overexpression
of SRp40 and SRp55 should cause an increase of exon 3
inclusion because the ISE3 element is intact. Consistently
with this prediction, the lower panel of Figure 2D shows
that the cotransfection of pApoA97T with SRp40 (lane 2)
and SRp55 (lane 6) promoted exon 3 inclusion. Conversely,
no variation in the levels of exon 3 inclusion was observed
whenthe constructcarryingthe mutated ISE wascotransfected
(lanes 4 and 8). Altogether these results indicate that both
SRp40 and SRp55 interact with the sequence named ISE3
and have a functionally positive effect on apoA-II exon 3
inclusion.
A G-rich element with context-dependent functions
is localized within apoA-II intron 2 and binds
hnRNP-H1
Analysis of the sequences upstream of the polypyrimidine
tract (GU repeated sequence) of exon 3 showed a region
between nt 1639 and 1666 composed of four G runs (namely
I2G1, I2G2, I2G3 and I2G4) (Figure 3A). Therefore, to test if
these elements could affect the splicing of apoA-II exon 3,
site-directed mutagenesis was carried out in these elements by
disrupting the single G runs using pApo A97T as template.
Figure 3B shows that the disruption of single I2G1 or I2G2
run rescued>90%ofexon 3inclusion, whereasmutagenesis of
G3 run rescued  60% of exon 3 inclusion (lanes 2–4, respect-
ively). Conversely, the disruption of G4 as well as of T run
immediately upstream of the G1 did not modify the splicing
pattern of the pApo-A97T construct (lanes 5 and 6, respect-
ively). Thus, these data suggest that G1, G2 and G3 runs have
a negative effect on exon 3 inclusion in the apoA-II context.
To conﬁrm the role of these elements in apoA-II exon 3 splic-
ing, we tested the effects of G runs mutagenesis also in the
pTBApo context (Figure 3D). Surprisingly, the disruption
of I2G1 and I2G2 runs caused >90% of exon 3 skipping
(Figure 3D, lanes 2 and 3). However, the mutagenesis of
Figure2.SRp40andSRp55interactwithISE-3sequenceandenhancesplicingofexon3.(A)Schematicrepresentationoftheconstructscarryingwild-type(ISE3wt)
and disrupted (ISE3m) ISE of apoA-II intron 3 used for the EMSA. (B) EMSA of ISE3wt and ISE3m RNAs incubated with HeLa nuclear extract. Complexes were
thenfractionatedona4%non-denaturingpolyacrylamidegel.ThepositionofRNA–proteincomplexes(uppercomplex—Ucandlowercomplex—Lc)andfreeRNA
are shown. Addition of nuclear extract is also indicated below the lane numbers (C) SDS–PAGE analysis of immunoprecipitation with the specific monoclonal
antibodyagainstthephosphorylatedRSdomain(MAb1H4)followingUV-crosslinkingofthelabeledRNAsISE3wt,ISE3mandhtotasapositivecontrol(plus)(31).
Specific immunoprecipitation of SRp40 (upper panel) and SRp55 (lower panel) is shown only with ISE3wt and htot RNAs. (D) Effects of SRp40 and SRp55
overexpression on apoA-II exon 3 splicing. Relative amounts of exon 3 skipping are indicated below the lane numbers. The variability among three different
experiments was always <20%.
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splicing pattern (Figure 3D, lane 4). Therefore, the function of
at least I2G1 and I2G2 runs in pTBApo do not mimic that in
the pApo context. In fact, in the apoA-II gene context, they
behave like an ISS, whereas in the pTBApo framework they
behave like an ISE. This result underscores the importance of
evaluatingpotential controlling regions in more than onemini-
gene system. Nonetheless, in order to identify the trans-acting
factors binding the G runs in the apoA-II intron 2 context, a
pull-down assay was performed with synthetic RNA oligo-
nucleotides containing either the I2G1 and I2G2 runs or the
same sequence carrying point mutations within them
(Figure 4A). This involved the crosslinking of transcribed
IVS2-G12w and IVS2n-G12m RNAs to adipic acid
dehydrazide agarose beads. Both beads preparations were
separately incubated with HeLa nuclear extracts and the pro-
teins bound were separated on an SDS–PAGE gel and then
analyzed by Coomassie blue staining. Figure 4B shows a
prominent band of  58 kDa molecular weight that could be
observed only with the IVS2-G12w RNA containing the intact
G runs. Considering that hnRNP-H1 is a splicing factor able
to bind G runs (11) a western blot analysis with a polyclonal
antibody against this protein was carried out thus conﬁrming
that the 58 kDa protein band corresponds to hnRNP-H1
(Figure 4C).
TDP-43 binds to (GU)16 repeats in apoA-II
intron 2 and represses exon 3 splicing
Our previous studies showed that, in the context of apoA-II,
the (GU)16 repeats seem to be important for exon 3 splicing
(5,12,13). However, we have also reported the identiﬁcation
of TDP-43 as a trans-acting factor able to interact with the
(GU)m polymorphic repeat region upstream from the 30 splice
site of the human CFTR exon 9 (6). In that report, it was
demonstrated that TDP-43 has an inhibitory effect on exon
9 inclusion in the CFTR mRNA (6). This observation led us
to investigate the possible role of this factor in the control of
the apoA-II exon 3 splicing. In order to conﬁrm the binding
of TDP-43 to the (GU)16 tract of apoA-II intron 2, we prepared
the construct mg(GU)16 that contains exon 2 and exon 3
sequences, the whole ﬂanking intron 2 as well as the 50 splice
Figure 3. A G-rich sequence within the human apoA-II intron 2 influences exon 3 splicing according to context. (A) Schematic representation of the different
constructs carrying point mutations in a regulatory sequence within the intron 2 in the pApo gene context. White boxes, thin lines and the black circle represent
the human apoA-II exons,introns and the (GT)16 tract, respectively. The ESEA97Tis indicatedas small black box withinthe apoA-II exon 3. Sequenceswithin the
apoA-II intron 2 changed by site-directed mutagenesis are indicated by small, white and gray circles. Partial sequence of the different constructs carrying point
mutationsintheintron2usedfortransfectioninHep3Bcellline.(B)AgarosegelelectrophoresisofRT–PCRproductsderivedfromconstructswithsingleGrunsor
T run disruption in the pApo context. (C) Schematic representation of the different constructs carrying point mutations within the intron 2 of the apoA-II in pTB
context. a-globin, fibronectin EDB exons and human apoA-II exon 3 are indicated in black, shaded and white boxes, respectively. Solid black lines, white box and
blackcirclerepresentthehumanapoA-IIintrons,exon3andthe(GT)16tract,respectively.TheESEwtisrepresentedbyasmallwhiteboxinsidetheexon3.Mutated
nucleotideswithintheapoA-IIintron2areindicatedbysmallwhiteandgraycircles.Partialsequenceofthedifferentconstructscarryingdisruptingpointmutations
within intron 2. (D) Splicing pattern analysis by ethidium bromide staining of a 2% agarose gel electrophoresis of the RT–PCR products derived from constructs
carryingsingleGrundisruptioninthepTBcontext.Relativeamountsofexon3skippingareindicatedbelowthelanenumbers.Thevariabilityamongthreedifferent
experiments was always <20%.
Nucleic Acids Research, 2005, Vol. 33, No. 18 6005site of intron 3 (Figure 5A). Moreover, two mutants where the
wholeGUrepeatedsequencewasremoved[mgD(GU)]oronly
a portion of IVS2 containing the GU tract with exon 3 and its
50 splice site [(GU)16-Ex3] were also prepared (Figure 5A).
These constructs were in vitro transcribed in the presence of
[a-
32P]UTP and equal quantities of labeled transcripts were
then used in a UV-crosslinking competition assay with HeLa
nuclear extract. Figure 5B shows that, among the proteins that
are crosslinked to the labeled mg(GU)16 RNA, the band with
the apparent molecular weight of 50 kDa was competed away
only when increasing amount of cold (GU)16-Ex3 RNA was
added, but not when cold mgD(GU) was used as competitor
(Figure 5B, compare lanes 1, 2 and 3 and 1, 4 and 5). Total
competition was observed whenthe same mg(GU)16unlabeled
RNA was added as control (Figure 5B).
In order to demonstrate that TDP-43 was the 50 kDa protein
binding the GU repeats, immunoprecipitation experiments
following the UV-crosslinking with a polyclonal antiserum
against TDP-43 was carried out. Constructs mg(GU)16 and
mgD(GU) were in vitro transcribed in the presence of
[a-
32P]UTP and equal amounts of labeled transcripts were
then used in a UV-crosslinking assay with HeLa nuclear
extract (data not shown). The UV-crosslinked samples were
subsequently immunoprecipitated with a polyclonal antiserum
against TDP-43 (6). Figure 5C shows that TDP-43 can be
speciﬁcally immunoprecipitated by the anti-TDP-43 anti-
serum following UV-crosslinking with nuclear extract of a
mg(GU)16 RNA, but not from a mgD(GU) control RNA.
siRNA against TDP43 highlights the negative influence
of this factor on apoA-II exon 3 splicing
In order to analyze the functional role that TDP-43 was
playing in the apoA-II context, knock down of this protein
was achieved through RNA-interference assay.
Double transfection of Hep3B cells at distance of 48 h with
siRNA speciﬁc sequence for TDP-43 was carried out. After
24 h of the second transfection with the siRNA against TDP-
43, constructs pApo-wt, pApo-A97T and pApo-ISE3m were
transiently transfected in the TDP-43 knocked down Hep3B
cells. Cell lysates were collected and analyzed for TDP-43
endogenous protein expression by western blot analysis
using anti-TDP-43 rabbit serum. After normalization of total
protein levels, we observed a strong reduction in the TDP-43
levels in Hep3B cells transfected with the TDP-43 siRNA, but
not in untreated cells or in cells treated with a control siRNA
(Figure 6A). Figure 6B shows the effects of TDP-43 silencing
on splicing pattern analysis after RT–PCR. An increase
in exon 3 inclusion was detected in cell transfected with
pApo-wt and, more importantly, total rescue of exon 3 inclu-
sion was observed in cells transfected with pApo-A97T
Figure 5. TDP-43 binds to the (GU) repeats in the apoA-II context.
(A) Diagrammatic representation of minigene constructs used for competition
experiments and immunoprecipitation with antibodies against TDP-43. Gray
andwhiteboxesrepresenttheapoA-IIexon2and3,respectively.Thinlinesand
blackcirclecorrespondtotheintronsandthe(GT)16repeats.Completedeletion
ofthe(GT)16tractintheconstructmgD(UG)isindicatedbyawhitecrossinthe
blackcircle.(B)UV-crosslinkingwithcompetitionanalysisfollowingaddition
of 5- to 10-fold molar excess of cold (GU)16-Ex3, mgD(GU) and mg(GU)16
RNAs to labeled mg(GU)16 RNA in the presence of HeLa nuclear extract.
(C) UV-crosslinking plus immunoprecipitation with anti-TDP43 serum.
[a-
32P]UTP-labeledmg(GU)16andmgD(GU)RNAswereincubatedwithHeLa
nuclear extract before UV-crosslinking. Immunoprecipitation was then carried
out with equal amounts of each UV-crosslinked sample using a polyclonal
antiserum against TDP-43.
Figure 4. ThehnRNPH1bindstoGrunswithinapoA-IIintron2.(A)Sequence
of two synthetic RNA oligos carrying the wild-type or the disrupted G runs
within the apoA-II intron 2 (IVS2-G12w and IVS2n-G12m, respectively). (B)
TheCoomassiestainedgelofapull-downassayusingadipicdehydrazidebeads
derivatized with the RNAs following incubation with HeLa nuclear extract. In
the lane from the IVS2-G12w-RNA-derivatized beads, the arrow indicates
the 58 kDa protein that is absent in the IVS2n-G12m-RNA-derivatized beads.
(C) Western blot analysis after the pull-down with the IVS2-G12w and
IVS2n-G12m RNA oligos to determine the amount of hnRNPH1 binding.
6006 Nucleic Acids Research, 2005, Vol. 33, No. 18and pApo-ISE3m (Figure 6B, compare lanes 4–5 and 7–8,
respectively).
These results further support the observation that the inter-
action of TDP-43 with GU repeats has a negative effect on
splicing of adjacent apoA-II exon 3, similarly to what has
been observed in the CFTR exon 9 context (14). Moreover,
these experiments highlight how the suppression of TDP-43
expression overrides the effect of disrupting the positive
splicing controlling elements such as the enhancers placed
in exon and intron 3.
DISCUSSION
Previous studies by our group have shown that human apoA-II
exon 3 contains at least one ESE that is important to balance
the low strength of its 30 splice site (5). In this paper we
considered that other elements, possibly located within ﬂank-
ing introns, might further contribute to the efﬁcient splicing
of exon 3.
A phylogenetic analysis of human apoA-II exon 3 and its
ﬂanking introns has evidenced that not only ESE sequence
within exon 3 but also three other sequences are conserved in
different species such as human, macaca, chimpanzee, mouse
and rat with respect to the base composition and to the distance
from the splice sites (Figure 7). The negative splicing element
(GU) tract within intron 2 is conserved in chimpanzee
(17 repeats) and Macaca fascicularia (7 repeats), whereas it
isvery short in rat (2repeats) or absent inmouse. Interestingly,
both the putative inhibitory G-rich element within intron 2 and
the positive element within exon 3are well conserved in all the
species.Conversely, the ISEwithin intron 3has alower degree
of homology in rodents (as compared with primate apoA-II
genes). Therefore, these gene rearrangements might
have placed negative cis-acting elements in proximity of
the 30 splice junction of apoA-II intron 2 and may have
activated an evolutionary selection of different mechanism
of splicing in order to improve the constitutive inclusion of
apoA-II exon 3.
There are several splicing control elements located within
introns (1,15). They can be involved in recognition of the
appropriate splice site or in the suppression or enhancement
of certain splice site usage, particularly in alternative splicing
cases.
Relatively little is known about the nature of the intronic
splicing controlling elements. Generally, they do not obey
deﬁned consensus rules and are known to consist of diverse
sequences (16) although some common intronic cis-acting
Figure 6. Knock down of TDP-43 causes the rescue of exon 3 inclusion. (A) Upper panel, western blot analysis of the cells treated with the siRNA oligonucleotide
against TDP-43 (siRNATDP43), control siRNA and mock transfected (lanes 1–3, respectively). TDP-43expression was probed by western blot using a polyclonal
antiserum. Lower panel, normalization control western blot with antibody against a-tubulin. (B) Shows splicing pattern analysis by ethidium bromide staining a
2%agarosegelofRT–PCRproductsaftercotransfectionofpApo-wt,pApo-A97TandpApo-ISE3malongwitheitherthesiRNATDP43(lanes1,4and7)oracontrol
siRNA oligonucleotides (lanes 2, 5 and 8). The transfection of different variants of pApo gene system with no siRNA oligonucleotide was included as a control
(lanes 3, 6 and 9).
Nucleic Acids Research, 2005, Vol. 33, No. 18 6007elements have been observed, suchasthe GGG triplet (17–19),
purine-rich sequences (20,21) or polypyrimidine tracts com-
monly present in the 30 as well as 50 regions of introns (22–24).
It is known that the potential localization of intronic splicing
cis-acting elements is extremely variable (20,25,26). We
therefore considered the possible presence of splicing control
elements in a range of 210 nt upstream of the exon 3 acceptor
site and 116 nt downstream of the exon 3 donor site. The
observation that the 26 nt-deletion of nt 1941–1967 in intron
3 causes exon 3 skipping strongly support the hypothesis that a
sequence that positively controls the inclusion of exon 3 lies
within that region. In a previous study, a purine-rich region
(AGGAGAAGGGA) within the ﬁbronectin EIIIB exon was
found to interact with SRp40 (27). It was shown that this
region is only partially responsible for stimulation of inclusion
during SRp40 overexpression, and probably this protein acts
at several different sites within the minigene. Interestingly,
a sequence with a high degree of homology with the above
described purine-rich region is present within the putative
ISE3 within apoA-II intron 3 (AGAAGGGA). In addition,
another study found that two GAR motifs are both required
for stable interaction of SRp55 within the cardiac troponin T
exon 5 (28). Moreover, it was noted that the binding of SRp55
to the target nucleotide sequence was efﬁcient only when the
wholecardiac troponinTexon 5was present, suggesting that it
can depend onRNA secondary structures.Indeed,inthe apoA-
II intron 3 context, the putative ISE-3 harbors a purine rich
sequence. Therefore, the concomitant binding of SRp40 and
SRp55 factors to the ISE3 region might occur, possibly by
engaging other sequences outside the nt range 1941–1967 that
spans the core of the ISE.
Previous studies on CFTR have shown that the interaction
of SR proteins with intronic sequences inhibits the inclusion
of the upstream proximal exon 9 in mRNA (7). However, there
are other examples of ISEs that affect positively splicing of
adjacent exons (29). The high contents of purines also might
beindicativeofa splicing control sequence sinceit seems tobe
the hallmark of these elements (3). In fact, we have demon-
strated that the splicing factors SRp40 and SRp55 speciﬁcally
bind the apoA-II transcript when ISE-3 is intact but not when
it is mutagenized. Indeed, the positive involvement of SR
proteins in apoA-II exon 3 splicing is supported by the fact
that their overexpression improves exon 3 inclusion.
On the other side of exon 3, apoA-II intron 2 also seems to
harbor different cis-acting elements involved in exon 3 splic-
ing. Interestingly, we have identiﬁed a G-rich splicing control
element whose activity is context-dependent: it has a silencer-
like behavior within its natural apoA-II context, whereas it
behaves like an enhancer-like element when placed in a het-
erologous context like that of ﬁbronectin EDB. One possible
explanation for this phenomenon is that the secondary
structure of the G-rich region might change according to
the context, so altering the accessibility of these sequences
as demonstrated previously (30–32). In this work, we have
shown that hnRNPH1 is one of the factors that bind to the G
runs within apoA-II intron 2. Recent studies on the distribution
ofGrunswithinintronshaveshownthattheyenhanceusageof
proximal splice sites (18,33,34). Furthermore, splicing of the
c-src N1 exon was shown to be mediated by an ISE located
downstream of the N1 50 splice site throughout interaction
with hnRNP H (35). Conversely, other reports show that
the G runs can have a silencer-like effect if placed within
exons by binding to hnRNP H (19,36–38). It is apparent
that our ﬁndings highlighted a G run-based cis-acting element
within apoA-II intron 2 whose peculiarity is given not only by
inhibiting splicing of the proximal downstream exon, but
also by the observation that its function can change according
to the intronic context where it is localized (Figure 3B
Figure7.EvolutionarycomparisonoftheregulatoryelementsfoundinhumanapoA-IIexon3anditsflankingintronsinhuman,macaca,chimpanzee,mouseandrat.
(A) SummaryofthesplicingcontrolelementsfoundinthehumanapoA-IIgene.Blackrectangleinintron2,whitesquareintheexon3andwhiterectangleinintron
3representtheISS,ESEandISEcis-actingelements,respectively.Exon3isindicated,thinlinesrepresentintrons,andtheblackcirclethe(GT)16tract.Thealignment
of the different splicing control elements in different species is shown along with the percentage of identity in comparison with human sequences. (B) Cartoon
showingaproposedmodelforthesplicingmechanismoftheapoA-IIexon3splicing.TDP-43andhnRNPH1preventtherecruitmentofU2AF65tothe30 splicesiteof
apoA-IIintron2.ASF/SF2andSC35interactingwiththeESEandSRp40andSRp55boundtotheISEmightcounteractthisnegativeeffectbyformingabridge-like
structure among components bound to the 50 and 30 splice sites permitting the definition of exon 3.
6008 Nucleic Acids Research, 2005, Vol. 33, No. 18and D). In addition to a possible role of RNA structure, this
context-dependent effect may also depend on interactions with
the other splicing regulatory elements that are speciﬁc for the
apoA-II gene. In addition, the enhancer/silencer activity might
be affected by splicing events preceding the deﬁnition of
apoA-II exon 3 or by the architecture of the transcriptional
machinery (both constructs have different promoters) as
demonstrated in other splicing models (39,40). Future studies
will be aimed at characterizing the mechanisms of splicing
control by G runs within IVS 2 and the role of hnRNP H1.
The other cis-acting element found close to the 30 splice site
of intron 2 consists in the (GU)16 repeats that were previously
shown to be functional as polypyrimidine tract (13). However,
it is important the context where it is located: in fact, the
replacement of the EDA exon polypyrimidine tract with the
apoA-II (GT)16 tract resulted in 95% of EDA exon exclusion
(5). Furthermore, previous experiments on the apoA-II model
showed that either the deletion of (GU)16 tract or its replace-
ment by (CA)16 promoted exon 3 skipping (5,12). In principle,
it could not be excluded that the deletion might cause exon
3 exclusion through alteration of branch point 30 splice site
spacing and that the replacement of (GU)16 by (CA)16 might
interfere with the 30 splice site deﬁnition because of the bind-
ing to another factor, such as hnRNP L that was recently
described as able to bind to (CA) repeats in the eNOS gene
(41). We now have conﬁrmed that the apoA-II (GU)16 repeats
are bound speciﬁcally by TDP-43 protein, similarly to what
happen in the CFTR intron 8 context (6). Considering that
TDP-43 has a detrimental role for CFTR exon 9 splicing, we
wondered if this factor might have a similar effect also in the
apoA-II intron 2 context and that this effect was counteracted
by the positive elements mapped above. Indeed, siRNA
experiments to knock down TDP-43 in Hep3B cells have
shown its inhibitory role also for apoA-II exon 3 splicing.
This ﬁnding overlaps what was observed with CFTR exon 9,
suggesting a general negative role of TDP-43 factors recruited
by (GU) repeats placed at the 30 splice site. Moreover, the
observation that the (GU) tract do not bind to U2AF65 (13)
suggest that different mechanisms for 30 splice site recognition
can exist. Altogether these observations further suggest that
the 30 splice site deﬁnition of the apoA-II exon 3 might be
supported by other strong cis-acting elements that can contrast
the negative effects of TDP-43 binding in proximity of the
30 splice site of exon 3. The question arises if all these
modulatory elements have evolved to counteract the negative
inﬂuence of the weak 30 splice site or have additional role in
apoA-II splicing. The negative effect of TDP-43 on exon 3
splicing is remarkably more evident when we transfected the
constructs pApo-A97T and pApo-ISE3m in cells where the
expression of that protein was blocked by siRNA: in fact,
TDP-43 silencing was able to fully rescue the effects of
both exonic and intronic enhancer mutations. This ﬁnding
suggests that apoA-II exon 3 deﬁnition can tolerate the dis-
ruption of splicing enhancers on condition that the inhibitory
effects of TDP-43 is relieved. It follows that exon 3 splicing
results from the coordinate action of positive cis-acting ele-
ments that balance the negative inﬂuence on apoA-II exon 3
splicing derived from the elements located at the 30 end of
intron 2. A large body of evidences indicates that U2AF35 is
required for constitutive splicing and also works as a mediator
of enhancer-dependent splicing (42). In vitro protein–RNA
interaction studies with pre-mRNAs containing either a
constitutive or regulated splicing enhancer have shown that
U2AF35 directly mediates interactions between U2AF65 and
proteins bound to the enhancers (43). On the basis of our data,
in the apoA-II intron 2 context, without enhancers, U2AF65
should not work efﬁciently owing to the weakness of the
polypyrimidine tract. We are temped to speculate that the
interaction of TDP-43 with (GU) repeats and of hnRNPH1
to the G runs within intron 2 might interfere the function
of U2AF65. Therefore, both the exonic and the intronic
enhancers might have a pivotal role in deﬁnition of exon 3.
However, the binding of ASF/SF2 and SC35 to the enhancer
within exon 3 as well as the interaction of SRp40 and SRp55
to the sequence within intron 3 might be crucial to recruit the
constitutive splicing factors U2AF35 and U2AF65 essential to
deﬁne the 30 splice site of intron 2. In this way, a bridge-like
structure among components bound to the 50 and 30 splice
sites would be formed to deﬁne exon 3 independently of the
polypyrimidine tract pathway.
ACKNOWLEDGEMENTS
This work was supported by grants from Telethon Onlus
Foundation—Italy (no. GGP02453) and F.I.R.B. (no.
RBNE01W9PM) to F.E.B. Funding to pay the Open Access
publication charges for this article was provided by ICGEB.
Conflict of interest statement. None declared.
REFERENCES
1. Smith,C.W. and Valcarcel,J. (2000) Alternative pre-mRNA splicing:
the logic of combinatorial control. Trends Biochem. Sci.,
25, 381–388.
2. Black,D.L. (2003) Mechanisms of alternative pre-messenger RNA
splicing. Annu. Rev. Biochem., 72, 291–336.
3. Blencowe,B.J. (2000) Exonic splicing enhancers: mechanism of action,
diversity and role in human genetic diseases. Trends Biochem. Sci.,
25, 106–110.
4. Hovhannisyan,R.H. and Carstens,R.P. (2005) A novel intronic cis
element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2
splicing through activation of an upstream exon and repression of a
downstream exon containing a noncanonical branch point sequence.
Mol. Cell. Biol., 25, 250–263.
5. Arrisi-Mercado,P., Romano,M., Muro,A.F. and Baralle,F.E. (2004)
An exonic splicing enhancer offsets the atypical GU-rich 30 splice
site of human apolipoprotein A-II exon 3. J. Biol. Chem., 279,
39331–39339.
6. Buratti,E., Dork,T., Zuccato,E., Pagani,F., Romano,M. and Baralle,F.E.
(2001) Nuclear factor TDP-43 and SR proteins promote in vitro and
in vivo CFTR exon 9 skipping. EMBO J., 20, 1774–1784.
7. Pagani,F., Buratti,E., Stuani,C., Romano,M., Zuccato,E., Niksic,M.,
Giglio,L., Faraguna,D. and Baralle,F.E. (2000) Splicing factors induce
CFTR exon 9 skipping through a non-evolutionary conserved intronic
element. J. Biol. Chem., 275, 21041–21047.
8. Buratti,E., Dork,T., Zuccato,E., Pagani,F., Romano,M. and Baralle,F.E.
(2001) Nuclear factor TDP-43 and SR proteins promote in vitro and
in vivo CFTR exon 9 skipping. EMBO J., 20, 1774–1784.
9. Cartegni,L., Wang,J., Zhu,Z., Zhang,M.Q. and Krainer,A.R. (2003)
ESEfinder: a web resource to identify exonic splicing enhancers.
Nucleic Acids Res., 31, 3568–3571.
10. Neugebauer,K.M. and Roth,M.B. (1997) Distribution of pre-mRNA
splicing factors at sites of RNA polymerase ImI transcription.
Genes Dev., 11, 1148–1159.
11. Matunis,M.J., Xing,J. and Dreyfuss,G. (1994) The hnRNP F protein:
uniqueprimarystructure,nucleicacid-bindingproperties,andsubcellular
localization. Nucleic Acids Res., 22, 1059–1067.
Nucleic Acids Research, 2005, Vol. 33, No. 18 600912. Shelley,C.S. and Baralle,F.E. (1987) Deletion analysis of a unique 30
splice site indicates that alternating guanine and thymine residues
representan efficient splicingsignal. NucleicAcidsRes.,15, 3787–3799.
13. Coolidge,C.J., Seely,R.J. and Patton,J.G. (1997) Functional analysis of
the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res.,
25, 888–896.
14. Buratti,E. and Baralle,F.E. (2001) Characterization and functional
implications of the RNA binding properties of nuclear factor TDP-43,
a novel splicing regulator of CFTR exon 9. J. Biol. Chem., 276,
36337–36343.
15. Ladd,A.N. and Cooper,T.A. (2002) Finding signals that regulate
alternative splicing in the post-genomic era. Genome Biol., 3,
reviews0008.
16. Fairbrother,W.G.andChasin,L.A.(2000)Humangenomicsequencesthat
inhibit splicing. Mol. Cell. Biol., 20, 6816–6825.
17. Carlo,T., Sterner,D.A. and Berget,S.M. (1996) An intron splicing
enhancer containing a G-rich repeat facilitates inclusion of a vertebrate
micro-exon. RNA, 2, 342–353.
18. McCullough,A.J. and Berget,S.M. (1997) G triplets located throughout a
classofsmallvertebrateintronsenforceintronbordersandregulatesplice
site selection. Mol. Cell. Biol., 17, 4562–4571.
19. Romano,M., Marcucci,R., Buratti,E., Ayala,Y.M., Sebastio,G. and
Baralle,F.E. (2002) Regulation of 30 splice site selection in the 844ins68
polymorphism of the cystathionine b-synthase gene. J. Biol. Chem.,
12, 12.
20. McCullough,A.J.andSchuler,M.A.(1997)Intronicandexonicsequences
modulate 50 splice site selection in plant nuclei. Nucleic Acids Res.,
25, 1071–1077.
21. Hastings,M.L., Wilson,C.M. and Munroe,S.H. (2001) A purine-rich
intronic element enhances alternative splicing of thyroid hormone
receptor mRNA. RNA, 7, 859–874.
22. Pagani,F., Buratti,E., Stuani,C., Bendix,R., Dork,T. and Baralle,F.E.
(2002) A new type of mutation causes a splicing defect in ATM.
Nature Genet., 30, 426–429.
23. Zuccato,E., Buratti,E., Stuani,C., Baralle,F.E. and Pagani,F. (2004)
An intronic polypyrimidine-rich element downstream of the donor site
modulates cystic fibrosis transmembrane conductance regulator exon 9
alternative splicing. J. Biol. Chem., 279, 16980–16988.
24. Hastings,M.L. and Krainer,A.R. (2001) Functions of SR proteins in the
U12-dependent AT-AC pre-mRNA splicing pathway. RNA, 7, 471–482.
25. Zheng,Z.M., Quintero,J., Reid,E.S., Gocke,C. and Baker,C.C. (2000)
Optimization of a weak 30 splice site counteracts the function of a bovine
papillomavirus type 1 exonic splicing suppressor in vitro and in vivo.
J. Virol., 74, 5902–5910.
26. Rowen,L., Young,J., Birditt,B., Kaur,A., Madan,A., Philipps,D.L.,
Qin,S., Minx,P., Wilson,R.K., Hood,L. et al. (2002) Analysis of the
human neurexin genes: alternative splicing and the generation of protein
diversity. Genomics, 79, 587–597.
27. Du,K., Peng,Y., Greenbaum,L.E., Haber,B.A. and Taub,R. (1997)
HRS/SRp40-mediatedinclusionofthefibronectinEIIIBexon,apossible
cause of increased EIIIB expression in proliferating liver. Mol. Cell.
Biol., 17, 4096–4104.
28. Nagel,R.J., Lancaster,A.M. and Zahler,A.M. (1998) Specific binding of
an exonic splicing enhancer by the pre-mRNA splicing factor SRp55.
RNA, 4, 11–23.
29. Gallego,M.E., Gattoni,R., Stevenin,J., Marie,J. and Expert-Bezancon,A.
(1997) The SR splicing factors ASF/SF2 and SC35 have antagonistic
effects on intronic enhancer-dependent splicing of the beta-tropomyosin
alternative exon 6A. EMBO J., 16, 1772–1784.
30. Buratti,E. and Baralle,F.E. (2004) Influence of RNA secondary structure
on the pre-mRNA splicing process. Mol. Cell. Biol., 24, 10505–10514.
31. Buratti,E., Muro,A.F., Giombi,M., Gherbassi,D., Iaconcig,A. and
Baralle,F.E.(2004)RNAfoldingaffectstherecruitmentofSRproteinsby
mouseandhumanpolypurinicenhancerelementsinthefibronectinEDA
exon. Mol. Cell. Biol., 24, 1387–1400.
32. Muro,A.F., Caputi,M., Pariyarath,R., Pagani,F., Buratti,E. and
Baralle,F.E. (1999) Regulation of fibronectin EDA exon alternative
splicing: possible role of RNA secondary structure for enhancer display.
Mol. Cell. Biol., 19, 2657–2671.
33. Sirand-Pugnet,P., Durosay,P., Brody,E. and Marie,J. (1995) An intronic
(A/U)GGG repeat enhances the splicing of an alternative intron of the
chicken beta-tropomyosin pre-mRNA. Nucleic Acids Res., 23,
3501–3507.
34. McCullough,A.J. and Berget,S.M. (2000) An intronic splicing enhancer
bindsU1snRNPstoenhancesplicingandselect50 splicesites.Mol.Cell.
Biol., 20, 9225–9235.
35. Chou,M.Y., Rooke,N., Turck,C.W. and Black,D.L. (1999) hnRNP H is a
component of a splicing enhancer complex that activates a c-src
alternative exon in neuronal cells. Mol. Cell. Biol., 19, 69–77.
36. Chen,C.D.,Kobayashi,R.andHelfman,D.M.(1999)BindingofhnRNPH
to an exonic splicing silencer is involved in the regulation of alternative
splicing of the rat beta-tropomyosin gene. Genes Dev., 13, 593–606.
37. Jacquenet,S., Mereau,A., Bilodeau,P.S., Damier,L., Stoltzfus,C.M. and
Branlant,C. (2001) A second exon splicing silencer within human
immunodeficiencyvirustype1tatexon2repressessplicingofTatmRNA
and binds protein hnRNP H. J. Biol. Chem., 276, 40464–40475.
38. Pagani,F., Buratti,E., Stuani,C. and Baralle,F.E. (2003) Missense,
nonsense,andneutralmutationsdefinejuxtaposedregulatoryelementsof
splicingincysticfibrosistransmembraneregulatorexon9.J.Biol.Chem.,
278, 26580–26588.
39. Cramer,P., Pesce,C.G., Baralle,F.E. and Kornblihtt,A.R. (1997)
Functional association between promoter structure and transcript
alternative splicing. Proc. Natl Acad. Sci. USA, 94, 11456–11460.
40. Pagani,F.,Stuani,C.,Zuccato,E.,Kornblihtt,A.R.andBaralle,F.E.(2003)
Promoter architecture modulates CFTR exon 9 skipping. J. Biol. Chem.,
278, 1511–1517.
41. Hui,J., Stangl,K., Lane,W.S. and Bindereif,A. (2003) HnRNP L
stimulates splicing of the eNOS gene by binding to variable-length CA
repeats. Nature Struct. Biol., 10, 33–37.
42. Graveley,B.R., Hertel,K.J. and Maniatis,T. (2001) The role of U2AF35
and U2AF65 in enhancer-dependent splicing. RNA, 7, 806–818.
43. Zuo,P. and Maniatis,T. (1996) The splicing factor U2AF35
mediates critical protein-protein interactions in constitutive and
enhancer-dependent splicing. Genes Dev., 10, 1356–1368.
6010 Nucleic Acids Research, 2005, Vol. 33, No. 18